瑞普生物半年报业绩增长57.59% 宠物供应链业务已覆盖1.3万客户

Core Viewpoint - The company, Reap Bio, reported significant growth in its financial performance for the first half of 2025, with a focus on innovation and strategic expansion in the animal health industry [1] Financial Performance - The company achieved a revenue of 1.708 billion yuan, representing a year-on-year increase of 20.53% - The net profit attributable to shareholders reached 257 million yuan, up 57.59% year-on-year - The net profit excluding non-recurring items was 188 million yuan, reflecting a growth of 34.28% - Basic earnings per share were 0.56 yuan [1] Innovation and R&D - Reap Bio emphasized technology-driven development, focusing on customer needs and launching new products in key areas such as vaccines and innovative drug formulations - The R&D investment amounted to 114 million yuan, accounting for 6.67% of revenue - The company received 4 new veterinary drug registration certificates and 6 clinical trial approvals, including the world's first clinical trial approval for an mRNA vaccine for food animals - The mRNA vaccine production line passed GMP certification, positioning the company among the first in China with industrialization capabilities for animal mRNA vaccines [2] Business Expansion and Market Strategy - The company is expanding into high-potential segments and overseas markets, leveraging a comprehensive service model that includes detection, monitoring, and product optimization - Reap Bio is collaborating with large clients to build disease monitoring platforms and enhance biosecurity measures throughout the customer lifecycle - The company is implementing innovative cooperation models with breeding groups to share risks and create value [3] Pet Healthcare Development - Reap Bio is advancing its pet healthcare strategy by integrating products, supply chains, and medical services - The supply chain integration has led to a more than 40% increase in the shipment volume of self-owned products - The company has established a service network covering 13,000 clients and is collaborating with a pharmaceutical company to enhance its pet healthcare offerings [4] Lean Transformation and Operational Efficiency - The company is focusing on lean transformation to reshape its profitability model, establishing a closed-loop operational management system - Key areas of focus include procurement, processes, and workforce efficiency, with 90 lean projects underway - Reap Bio aims to strengthen its lean organization and implement projects in its benchmark bases for biological products and chemical drugs [4]